MetLife (MET)
(Delayed Data from NYSE)
$78.56 USD
+0.13 (0.17%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $78.57 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$78.56 USD
+0.13 (0.17%)
Updated Nov 4, 2024 04:00 PM ET
After-Market: $78.57 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value F Growth F Momentum C VGM
Zacks News
Why MetLife (MET) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does MetLife (MET) have what it takes? Let's find out.
Aflac's (AFL) Japan Business to Drive Long-Term Growth
by Zacks Equity Research
Changes in Japan's economy and aging population is likely to drive growth at Aflac (AFL).
Why MetLife (MET) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does MetLife (MET) have what it takes? Let's find out.
Why Is MetLife (MET) Up 1.8% Since Last Earnings Report?
by Zacks Equity Research
MetLife (MET) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Research Reports for McDonald's, CVS Health & Celgene
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including McDonald's (MCD), CVS Health (CVS) and Celgene (CELG).
CNO Financial's (CNO) Q4 Earnings Lag Estimates, Fall Y/Y
by Zacks Equity Research
CNO Financial's (CNO) fourth-quarter earnings fall shy of estimates due to lower revenues.
Q4 Earnings Drive Insurance ETFs Higher
by Sweta Killa
The Q4 earnings of insurance industry players had a positive impact on the related ETFs that saw smooth trading over the past month.
Why MetLife (MET) is a Top Dividend Stock for Your Portfolio
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does MetLife (MET) have what it takes? Let's find out.
MetLife (MET) Q4 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
MetLife's (MET) Q4 earnings gain from a decline in total expenses and revenues remain flat year over year.
Insurers' Q4 Earnings Roster for Feb 6: MET, PRU, CINF, LNC
by Zacks Equity Research
Insurers are likely to benefit from interest rate hikes, improved pricing, continued share repurchases, though cat loss will weigh on underwriting profitability.
Factors Likely to Shape MetLife (MET) This Earnings Season
by Zacks Equity Research
MetLife (MET) fourth-quarter 2018 earnings should gain from increase in revenues and accretion from share buyback program, partly offset by catastrophe losses.
MetLife (MET) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
MetLife (MET) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MGIC Investment (MTG) Q4 Earnings Beat, Revenues Up Y/Y
by Zacks Equity Research
MGIC Investment (MTG) Q4 results reflect lower credit losses, improved net premiums earned, and impact of lower tax and share buybacks.
Are Investors Undervaluing MetLife (MET) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why You Should Add Assurant (AIZ) to Your Portfolio
by Zacks Equity Research
Assurant (AIZ) rides on operational excellence and promises better rewards for investors.
MetLife (MET) Gains As Market Dips: What You Should Know
by Zacks Equity Research
MetLife (MET) closed at $43.72 in the latest trading session, marking a +0.81% move from the prior day.
CNO Financial's Subsidiaries Get Ratings From A.M. Best
by Zacks Equity Research
CNO Financial's (CNO) arms receive rating actions from A.M. Best. Outlook is stable.
Why MetLife (MET) is Worth Adding to Your Portfolio Now
by Zacks Equity Research
Business streamlining and a solid balance sheet poise MetLife for growth in 2019.
Zacks.com featured expert Kevin Matras highlights: Gulfport Energy, MetLife, Fiat Chrysler Automobiles, CVS Health and Barclays
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Gulfport Energy, MetLife, Fiat Chrysler Automobiles, CVS Health and Barclays
5 Best GARP Picks with Discounted PEG
by Zacks Equity Research
To make a long-term investment more effective, the principles of both value and growth investing need to be combined.
Why Hold Strategy is Apt for Aon (AON) in Your Portfolio
by Zacks Equity Research
Backed by top-line growth, strategic endeavors and a solid cash trunk, Aon (AON) holds great potential to earn good returns for investors.
Zacks.com featured expert Kevin Matras highlights: Tech Data, ArcBest, MetLife, Gulfport Energy and Colfax
by Zacks Equity Research
Zacks.com featured expert Kevin Matras highlights: Tech Data, ArcBest, MetLife, Gulfport Energy and Colfax
Is MetLife (MET) Stock Outpacing Its Finance Peers This Year?
by Zacks Equity Research
Is (MET) Outperforming Other Finance Stocks This Year?
6 Promising Price-to-Book Value Stocks to Buy Now
by Zacks Equity Research
P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high growth prospects.
Cigna (CI) & Units Receive Rating Actions From A.M. Best
by Zacks Equity Research
Credit rating giant A.M. Best affirms the ratings of Cigna (CI) and its subsidiaries.